| Systematic (IUPAC) name | |
|---|---|
| 1-(4-chlorophenyl)-2-methylpropan-2-yl 2-aminopropanoate | |
| Identifiers | |
| CAS number | 60719-82-6 60719-83-7 (hydrochloride) |
| ATC code | N06AB07 |
| PubChem | 2081 |
| ChemSpider | 1997 |
| Chemical data | |
| Formula | C13H18ClNO2 |
| Mol. mass | 255.740 g/mol |
| SMILES | eMolecules & PubChem |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Alaproclate (GEA-654) is a psychoactive drug and research chemical derived from zimelidine (Normud, Zelmid) that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies.
See also
References
|
|
This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (December 2007) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)




